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https://doi.org/10.1186/s13024-018-0291-3RESEARCH ARTICLE Open AccessA brain-penetrant triazolopyrimidine
enhances microtubule-stability, reduces
axonal dysfunction and decreases tau
pathology in a mouse tauopathy model
Bin Zhang1, Yuemang Yao1, Anne-Sophie Cornec2, Killian Oukoloff3, Michael J. James1, Pyry Koivula1,
John Q. Trojanowski1, Amos B. Smith III2, Virginia M.-Y. Lee1, Carlo Ballatore3* and Kurt R. Brunden1*Abstract
Background: Alzheimer’s disease (AD) and related tauopathies are neurodegenerative diseases that are characterized
by the presence of insoluble inclusions of the protein tau within brain neurons and often glia. Tau is normally found
associated with axonal microtubules (MTs) in the brain, and in tauopathies this MT binding is diminished due to tau
hyperphosphorylation. As MTs play a critical role in the movement of cellular constituents within neurons via axonal
transport, it is likely that the dissociation of tau from MTs alters MT structure and axonal transport, and there
is evidence of this in tauopathy mouse models as well as in AD brain. We previously demonstrated that
different natural products which stabilize MTs by interacting with β-tubulin at the taxane binding site provide
significant benefit in transgenic mouse models of tauopathy. More recently, we have reported on a series of
MT-stabilizing triazolopyrimidines (TPDs), which interact with β-tubulin at the vinblastine binding site, that
exhibit favorable properties including brain penetration and oral bioavailability. Here, we have examined a
prototype TPD example, CNDR-51657, in a secondary prevention study utilizing aged tau transgenic mice.
Methods: 9-Month old female PS19 mice with a low amount of existing tau pathology received twice-weekly
administration of vehicle, or 3 or 10 mg/kg of CNDR-51657, for 3 months. Mice were examined in the Barnes
maze at the end of the dosing period, and brain tissue and optic nerves were examined immunohistochemically or
biochemically for changes in MT density, axonal dystrophy, and tau pathology. Mice were also assessed for changes in
organ weights and blood cell numbers.
Results: CNDR-51657 caused a significant amelioration of the MT deficit and axonal dystrophy observed in
vehicle-treated aged PS19 mice. Moreover, PS19 mice receiving CNDR-51657 had significantly lower tau
pathology, with a trend toward improved Barnes maze performance. Importantly, no adverse effects were
observed in the compound-treated mice, including no change in white blood cell counts as is often observed in
cancer patients receiving high doses of MT-stabilizing drugs.
Conclusions: A brain-penetrant MT-stabilizing TPD can safely correct MT and axonal deficits in an established mouse
model of tauopathy, resulting in reduced tau pathology.
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The tauopathies are neurodegenerative diseases charac-
terized by the presence of insoluble inclusions of the tau
protein within brain neurons and often glia. These tau
accumulations are referred to as neurofibrillary tangles
(NFTs) when found in the neuronal soma and neuropil
threads (NTs) when found in dendritic processes [1, 2].
AD is the most prevalent tauopathy, where the hallmark
pathologies are NFT, NT and neuritic plaque-associated
tau inclusions, as well as senile plaques comprised of
amyloid β peptides [3]. In contrast, neuronal and/or glial
tau inclusions are the primary pathology in other tauo-
pathies that include progressive supranuclear palsy
(PSP), corticobasal degeneration (CBD), Pick’s disease
and other frontotemporal lobar degenerative (FTLD)
conditions [1]. There is a strong correlation between tau
pathological burden in the brain and cognitive decline in
AD [4–6], a finding bolstered by recent tau positron
emission tomography imaging studies in AD [7, 8] and
FTLD due to tau pathology [9, 10], suggesting that it is
the development of abundant tau inclusions that ultim-
ately leads to the neurodegeneration observed in AD
and the other tauopathies. That tau mutations lead to fa-
milial cases of FTLD with NFTs and NTs [11, 12] further
confirms that misfolded tau oligomers and/or inclusions
are sufficient to cause neurodegeneration.
Tau is normally found associated with axonal MTs in
the brain, and in tauopathies this MT binding is dimin-
ished due to tau hyperphosphorylation [13–15], facilitat-
ing tau deposition into the fibrillar accumulations that
comprise NFTs and NTs. Tau binding to MTs is thought
to reduce MT dynamicity, particularly at the more labile
distal portions of MTs [16, 17], thereby providing in-
creased stability to this region of axonal MTs either dir-
ectly [18] and/or through inhibition of MT-severing
enzymes [19, 20]. As MTs play a critical role in the
movement of vesicles, mitochondria and other cellular
constituents within neurons via axonal transport [21], it
is likely that the dissociation of tau from MTs in tauopa-
thies alters both MT structure and axonal transport, al-
though the observation of axonal transport deficits in
other neurodegenerative diseases with neuronal protein
inclusions (e.g., Parkinson’s disease and amyotrophic lat-
eral sclerosis) suggests that inclusions themselves may
affect MT structure and/or function [22]. There is com-
pelling evidence of MT abnormalities in neuronal [23]
and transgenic (Tg) mouse models [24–27] of tauopathy,
with the latter showing decreased MT density, increased
MT dynamicity, and slowed axonal transport. MT defi-
cits have also been observed in AD brain [28–30], and it
is thus likely that altered MT structure and function
contributes to the neurodegenerative processes in tauo-
pathies [31]. In fact, studies from our laboratories and
others have revealed that treatment of tau Tg mice withbrain-penetrant MT-stabilizing natural products such as
epothilone D (EpoD) and dictyostatin improves a num-
ber of CNS outcomes, with enhanced MT density,
axonal transport, neuron survival, and cognitive per-
formance with a reduction of tau pathology [24, 25, 27,
32]. Notably, EpoD proved to be particularly safe and ef-
ficacious in tauopathy models, and EpoD (BMS-241027)
subsequently advanced to Phase 1b testing in AD pa-
tients (ClinicalTrials.gov identifier NCT01492374),
where it was found to be safe in a 9-week trial.
Given the therapeutic potential of brain-penetrant
MT-stabilizing compounds, we have recently evaluated
non-naturally occurring small molecule MT-stabilizing
agents, with the goal of identifying alternative and
potentially improved candidates for development as
disease-modifying drugs for AD and other neurodegenera-
tive conditions. These efforts led to the characterization of
a series of brain-penetrant TPD and phenylpyrimidine
(PPD) MT-modulating molecules [33–35] that, when
compared to EpoD and dictyostatin, exhibit several favor-
able features including oral bioavailability, lack of
P-glycoprotein (Pgp) interaction and ease of synthesis.
Notably, the mechanism of action of these MT-active
small molecules is believed to be unique and distinct from
that of EpoD, dictyostatin and other MT taxane-site
binders, as binding [36, 37] and X-ray crystallography [38]
studies revealed that TPDs interact with β-tubulin at a site
that largely overlaps with the vinblastine binding site. An
evaluation of representative PPD and TPD examples re-
vealed an unexpected divergence of MT-directed activity
of these molecules, in which all active PPDs and a large
proportion of active TPDs demonstrated a bell-shaped
concentration-response profile when markers of stabilized
MTs (i.e., acetylated and detyrosinated α-tubulin [39], or
AcTub and GluTub, respectively) were quantified in cellu-
lar assays [35]. Moreover, the PPD and TPD molecules
that elicited this unusual concentration-response caused
MT disruption at higher concentrations, as visualized by
immunocytochemistry, with an associated proteasome-
mediated degradation of cellular tubulin [35]. In contrast,
a subset of the TPD molecules (referred to as TPD+
compounds) elicited linear concentration-dependent in-
creases in stable MT markers and in cellular MT mass in
both transformed cells and primary neuron cultures.
Moreover, a prototype TPD+ molecule (CNDR-51657;
hereafter 51657, structure in Fig. 1a) was shown to rescue
neuron cultures from axonal damage resulting from
MT-destabilization [35]. In addition, 51657 was shown to
increase brain AcTub in wild-type (WT) mice after a sin-
gle administration [35].
Here, we have selected 51657 as a prototype TPD+
compound for more complete in vivo characterization,
including efficacy testing in the PS19 tau Tg mouse
model of tauopathy [40]. We reveal that 51657 provided
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Fig. 1 PK and pharmacodynamic profiling of 51657. a Plasma and
brain levels of 51657 (structure inset) after a 5 mg/kg i.p. dose. Brain
levels exceed plasma levels at all times, with terminal plasma and
brain T1/2 values of 1–1.5 h. Error bars represent SEM, with n = 3 per
time point. b Levels of brain AcTub in WT mice 3 days after the last
dose of vehicle or 10 mg/kg of 51657. Error bars represent SEM of
n = 3 per treatment, with an unpaired t-test used to determine
significance of compound effect
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duced axonal dystrophy and a significant reduction of
brain tau pathology, features that closely resemble the
salutary effects previously obtained with EpoD. These data
demonstrate that a MT-stabilizing agent that interacts
with MTs at a site distinct from the taxane/epothilone
binding site can provide benefits in a neurodegenerative
disease model that are comparable to those observed with
taxane-site binders. Thus, TPD+ molecules hold promise
as potential therapeutic agents for AD and other neurode-
generative diseases.Methods
Compound synthesis
The synthesis of 51657 was conducted at the 0.5 g scale
following procedures described previously [35]. The
spectroscopic properties of the compound were identical
to those reported in the literature. In addition, single
crystal x-ray diffraction analysis of the final compound
was conducted (see Supplemental Information).ADR-RES cytotoxicity assay
ADR-RES cells (NCI) were maintained in RPMI medium
(Mediatech) containing 10% FBS, 2 mM L-glutamine, and
1% penicillin/streptomycin (complete RPMI) at 37 °C in
5% CO2. For compound testing, cells were dissociated
with trypsin/EDTA and plated at a density of 3000 cells/
well in black 96-well clear-bottom plates (Perkin-Elmer)
in 0.1 ml of complete RPMI medium, followed 24 h later
by the addition of paclitaxel or 51657 diluted from 10 mM
DMSO stock solutions that were diluted into complete
RPMI medium (0.1 ml total added to existing medium;
final compound concentration of 1 μM). In addition, wells
were also treated with 0.1 ml of vehicle alone (final con-
centration of 0.01% DMSO on cells). Cells were main-
tained at 37 °C in 5% CO2 and at 72 h after compound
addition, 20 μl of Alamar Blue cell viability reagent (Invi-
trogen) was added to the wells and allowed to incubate for
4 h at 37 °C in 5% CO2 followed by measurement in a
SpectraMax M5 plate reader with excitation of 550 nm
and emission of 590 nm with a cutoff of 570 nm. A set of
vehicle-treated wells were treated with digitonin (final
concentration of 0.5%) at the time of compound addition
to kill cells and elicit the minimal Alamar Blue signal. The
percent cell viability was calculated as 100 × (Test-Digito-
nin)/(Vehicle-Digitonin).
Microsomal metabolism of 51657
Pooled human and mouse liver microsomes (Corning
Life Sciences) were utilized at a concentration of 1 mg/
ml with a NADPH regenerating system as per vendor in-
structions. Compound (51657) was added at 1 μM in the
absence or presence of CYP450 inhibitors, and aliquots
of the reaction mixture were removed at 10 min inter-
vals for 60 min. Acetonitrile was added to the sampled
reactions at 3:1 (v/v) and the mixtures were vortexed
and centrifuged, with the supernatant subjected to
LC-MS/MS analysis as previously described [35].
Mouse studies
All methods utilizing mice were first submitted and ap-
proved by the University of Pennsylvania Institutional
Animal Care and Use Committee (IACUC).
Analysis of plasma and brain compound concentrations
Test compound was administered to 2–4 month old CD-1
or B6SJL mice, with both female and male mice utilized
but sexes were not mixed within experimental groups. For
standard single time-point brain and plasma determina-
tions, groups of mice (n = 3) were injected intraperitone-
ally (i.p.) with a single dose of 5 mg/kg compound
dissolved in DMSO. For pharmacokinetic analysis, groups
of mice (n = 3) were sacrificed at various times points after
i.p. dosing of 5 mg/kg of compound. Whole brain hemi-
spheres were homogenized in 10 mM ammonium acetate,
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Plasma was obtained from blood collected in 0.5 M EDTA
solution and centrifuged for 10 min at 4,500 × g at 4 °C.
The analysis of compound concentrations in plasma and
brain homogenates was as previously described [35].
Brain AcTub determinations
CD-1 female mice (n = 3; 2–3 months of age) received
three i.p. injections of 10 mg/kg of 51657 spaced 72 h apart.
After 72 h following the third injection, mice were eutha-
nized by an IACUC-approved protocol and cortices were
dissected from each brain and placed immediately in
ice-cold RIPA buffer (50 mM Tris, 150 mM NaCl, 5 mM
EDTA, 0.5% sodium deoxycholate, 1% NP-40, 0.1% SDS,
pH 8.0) containing protease -inhibitor cocktail (Sigma
Aldrich), 1 mM phenylmethylsulfonyl fluoride (PMSF)
(Sigma Aldrich), and 3 μM trichostatin A (Sigma Aldrich).
Tissue was homogenized with a hand-held battery operated
pestle motor mixer and then sonicated to complete the
lysis. Samples were centrifuged at 100,000 × g for 30 min at
4 °C and supernatant was transferred to a new Eppendorf
tube. Remaining pellets were re-suspended in RIPA buffer
and homogenized, sonicated, and centrifuged again, as be-
fore. Supernatant from the second centrifugation step was
pooled with that from first spin. Samples were assessed for
protein concentration by bicinchoninic acid (BCA) assay
(Thermo Fisher Scientific) and enzyme-linked immuno-
sorbent assay (ELISA) analysis of acetyl- and alpha-tubulin
levels was performed, as previously described [35, 41].
51657 Treatment of PS19 Tg mice
PS19 mice [40] express a transgene encoding the human
T34 tau isoform (1N4R) containing the P301S mutation
found in inherited FTLD-tau [42]. Groups of 9-month
old female PS19 mice (B6C3/F1 background as described
[40]) were administered twice-weekly i.p. injections of
3 mg/kg or 10 mg/kg of 51657 at a volume of 2 μl/g
body weight, or vehicle only (9% DMSO/91% corn oil),
for a total of 12 weeks. An additional group of
age-matched non-transgenic female littermates were
treated with vehicle as above. Mice entered into the
study in 4 separate cohorts spaced over 4 months, with
each cohort having all groups represented such that the
final group size of all treatment arms reached n = 12. All
mice were monitored for signs of abnormal behavior or
distress, and were weighed weekly to monitor body
weight. After 11 weeks of dosing, the mice from 3 of 4
study cohorts underwent Barnes maze testing as de-
scribed below. After sacrifice by an IACUC-approved
protocol, blood was collected from 3 of 4 study cohorts
for complete blood cell counts, as described [25]. Simi-
larly, the optic nerve (ON), which harbors tau pathology
together with retinal ganglia cells in these mice [25], was
recovered from 3 of 4 study cohorts for transmissionelectron microscopy (EM) analysis of axonal dystrophy
and MT density. Brains were collected from all study
mice for biochemical and immunohistochemical ana-
lyses, and organ weights were recorded to assess com-
pound tolerability.
Body weights, organ weights and complete blood cell
counts
Study mice were weighed once-weekly during the course
of the dosing period. Upon sacrifice and perfusion, key
organs were collected and weights determined. Blood
samples from a subset of the study WT and PS19 mice,
as indicated in the figure legend, were sent to an outside
vendor (7th Wave Laboratories, St. Louis, MO) for
complete blood cell analyses.
ON axonal dystrophy and MT density analyses
EM was performed on cross sections of ON from
vehicle- or 51657-treated WT and PS19 mice to as-
sess MT density and axonal dystrophy, as previously
described [27, 32].
Immunoblot analysis of insoluble brain tau
Combined cortex and hippocampus samples (~ 40–
50 mg) from frozen hemispheres of vehicle- and
51657-treated PS19 mice were homogenized in 0.2 ml of
RAB high salt buffer (0.1 M MES, 1 mM EGTA, 0.5 mM
MgSO4, 0.75 M NaCl, 0.02 M NaF, pH 7.0), and the ho-
mogenates were centrifuged at 100,000 × g for 30 min at
4 °C. The resulting pellet was resuspended in 0.2 ml
RAB buffer and centrifuged as above, followed by an-
other resuspension in 0.3 ml of RAB buffer followed by
centrifugation. The remaining pellet was resuspended in
0.2 ml of RIPA buffer (50 mM Tris, 150 mM NaCl, 0.1%
SDS, 0.5% sodium deoxycholate, 1% NP40 and 5 mM
EDTA), followed by centrifugation as above. This pellet
was resuspended in 0.1 ml of 2% SDS and sonicated,
followed by centrifugation at 100,000 × g for 30 min at
22 °C. The SDS pellet was resuspended in 0.1 ml of 2%
SDS followed by sonication and centrifugation, and the
resulting supernatant was combined with the first SDS
supernatant. This combined SDS supernatant fraction
was utilized for SDS-PAGE analysis and immunoblotting
as previously described [35], using a rabbit polyclonal
antibody recognizing total tau (17205 [43]; developed
in-house, RRID:AB_2315435, used at 1:2000 dilution of
sera in Li-Cor blocking buffer), a rabbit polyclonal anti-
body recognizing tau containing an acetyl modification
at lysine residue 280 (TauAcK280; developed in-house
[44], used at 1:2000 dilution of sera in Li-Cor blocking
buffer) or the AT8 monoclonal antibody (ThermoFisher)
that recognizes tau that is phosphorylated at serine
residue 202 and/or threonine residue 205 (1:2000
dilution of sera in Li-Cor blocking buffer). Immunoblots
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(Li-Cor) and relative protein amounts were quantified
from the immunoblots using ImageStudio software
(Li-Cor). Because the majority of the total protein, in-
cluding housekeeping proteins, are extracted into the
RAB-soluble fraction, the RAB-insoluble, SDS-soluble
brain samples from each PS19 mouse were loaded onto
SDS-PAGE gels at equal protein amounts based on the
corresponding RAB-soluble protein concentration. More
specifically, RAB-insoluble samples, which were all
solubilized in equal volumes of SDS as described above,
were prepared for SDS-PAGE such that the amounts
loaded corresponded to 0.25 mg/ml of the RAB-soluble
fraction. For example, if the RAB-soluble protein con-
centration was 2 mg/ml, the RAB-insoluble sample was
diluted 8-fold for SDS-PAGE analysis. To provide fur-
ther normalization accuracy, corresponding samples of
the RAB-soluble fractions diluted to 0.25 mg/ml were
loaded onto separate SDS-PAGE gels and blotted for the
housekeeping protein, GAPDH. The immunoblot densi-
tometric values for the tau species from the RAB-
insoluble samples for each mouse were then normalized
to the corresponding GAPDH densitometric value from
the RAB-soluble sample (see Additional file 1: Figure S6
for representative blot images). All samples for immuno-
blot analyses were coded so as to mask the sample
identification throughout the immunoblot procedure, in-
cluding during densitometric quantification of the tau
and GAPDH bands.
Tau ELISA
The RAB-soluble fractions from brain homogenates of
vehicle- and 51657-treated PS19 mice (see above) were
assessed for total tau utilizing a sandwich ELISA essen-
tially as previously described [27], with volumes of the
samples adjusted based on total protein content in the
RAB-soluble fraction as determined by BCA assay.
AT8 immunohistochemistry
Study mice were perfused with PBS (20 ml) after being
deeply anesthetized using a protocol approved by the
University of Pennsylvania IACUC. The brains were sub-
sequently removed and one hemisphere from each
mouse was processed as previously described [25, 27],
with 6 μm thick paraffin-embedded sections prepared
and stained with the AT8 antibody (1:2000 dilution) that
recognizes tau phosphorylated at S202/T205 [45]. Im-
munostained sections that were masked to treatment
group were imaged using a 4× microscopic objective.
For analysis of hippocampal neurons, 3 matched brain
sections (Bregma: − 2.20 to − 2.80) from vehicle- and
51657-treated PS19 mice were manually annotated
around the entire hippocampus and entorhinal cortex
using HALO (Indica Labs, Corrales, NM) software.Sections representing average AT8 staining intensity
were thresholded to allow quantification of tau path-
ology in the hippocampal and cortical sections without
contribution of background staining, and a common
threshold was then applied to all sections. Quantification
was conducted with the HALO software. The area of tau
pathology within each annotated region was determined,
and this was summed across the three individual sec-
tions from each mouse and divided by the sum of the
total annotated area from the three sections to get the
total % area with tau pathology. This value was multi-
plied by the average optical density (OD) of the tau
pathology to yield the final “normalized AT8 area x
OD”, and the sum of these values from the hippocampal
and cortical assessments are reported.NeuN immunohistochemistry
Quantification of CA3 neurons was performed using
NeuN antibody to label neuronal nuclei [46]. Staining
was performed as noted above for AT8 staining, using a
mouse anti-NeuN antibody (Millipore; 1:500). Two
bregma levels (Bregma: − 1.82 and − 1.94) containing the
CA3 region of the hippocampus were used for analyses.
Slides were blinded and scanned using a Perkins Elmer
Lamina slide scanner. ImageJ (NIH) was used for NeuN
image analysis and quantification. Briefly, RGB TIFF im-
ages were converted to 8-bit images and then inverted.
Max entropy auto-thresholding was used on all images
and the CA3 region of the hippocampus was annotated
manually using morphological landmarks in the mouse
brain. Percent NeuN-positive area was then used as a
readout for neuronal density, with the data decoded and
compiled by an independent investigator.GFAP and Iba1 immunofluorescence
Paraffin-embedded sections (6 μm; Bregma − 2.5)
from PS19 mouse brains receiving vehicle or 51657
(n = 3/group) as above were deparaffinized through a
5 min incubation in xylene followed by graded rehy-
dration in ethanol solutions (100%, 95%, 80% and
75% for 1 min each). The sections then underwent
antigen retrieval through addition of a citrate-based
antigen unmasking solution (Vector Labs) followed by
microwave treatment at 99 °C for 15 min. After
washing of slides in 0.1 M Tris, the slides were
stained with GFAP (rat 2.2B10 hybridoma super-
natant; RRID:AB_2532994) and Iba1 (rabbit poly-
clonal; Dako) that were each diluted 1:1000 in 0.1 M
Tris containing 2% fetal bovine serum, utilizing fluor-
escent anti-rat (AF594, 1:700; ThermoFisher) or
anti-rabbit (AF488, 1:700; Wako) secondary anti-
bodies. Images were then captured using a fluores-
cence microscope.
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Barnes Maze testing was performed as previously de-
scribed [47] by an experimenter blinded to the treatment
groups. Briefly, mice were handled for 3 days prior to
Barnes Maze testing to get accustomed to the experi-
menter. Mice were habituated to the testing room for
30 min prior to testing each day. Mice were then placed
in the center of Barnes Maze (San Diego Instruments,
White 7001–0235) in the starting cylinder for 30 s. The
starting cylinder was then removed and mice were
allowed to explore the Barnes Maze for 2.5 min. If the
mouse did not find the target box, the mouse was gently
guided into the target box. The mice were allowed to re-
main in the target box for 1 min before returning them
to their home cage. Two trials per mouse were performed
each day with a 15-min inter-trial interval. Mice were
tested for 4 consecutive days. The percent success was de-
termined based on the mouse’s first encounter (≥ 2 s) with
the target box, termed primary success. Primary measures
were used because some mice would successfully locate
the target box yet continue to explore the maze, a behav-
ior which has been reported previously [48].
Statistics
GraphPad Prism 7 was utilized for all statistical analyses.
Comparisons between treatment groups consisted of un-
paired t-tests when comparing two groups, or one-way
ANOVA analyses with Tukey post-hoc analysis to com-
pare between groups when comparing more than two
groups. Grubb’s tests (GraphPad QuickCalc) were ap-
plied to the data to query for extreme outliers, and when
found (as noted in figure legends) these outliers were re-
moved from the data analysis.
Results
Pharmacokinetic (PK) and Pharmacodynamic properties of
CNDR-51657
Among the TPD+ compounds, 51657 (Fig. 1a) was
chosen as a prototype for full in vivo characterization.
Prior analyses demonstrated that 51657 is orally bio-
available and has excellent brain penetration, with a
brain-to-plasma (B/P) exposure ratio of ~ 2.7 at 1 h after
i.p. dosing [35]. A more complete PK analysis of 51657
in WT mice confirmed that total brain exposure
exceeded that in plasma, with terminal brain and plasma
T1/2 values of ~ 1.0–1.5 h (Fig. 1a). Although the T1/2 of
51657 is somewhat short, we had previously demon-
strated that a single 1 mg/kg i.p. dose increased WT
mouse brain AcTub one day after administration, indi-
cating target engagement and increased MT stability
[35]. In further analyses, we found that a 10 mg/kg dose
of 51657 administered once every 3–4 days over 7 days
to WT mice resulted in elevated brain AcTub that per-
sisted for 72 h after the final dosing (Fig. 1b). Given thatthe compound is eliminated from the brain relatively
quickly, this prolonged MT activity suggests that brain
MTs retain stability for an extended period after drug
clearance. Alternatively, an active metabolite of 51657
may be formed with significantly longer brain retention
than the parent compound. However, we have investi-
gated the metabolism of 51657 in mouse and human
microsomal studies and found that the molecule is me-
tabolized by several CYP450 enzymes to release an in-
active N-dealkylated derivative (Additional file 1: Figure
S1A & B). An examination of mouse plasma and brain
homogenates confirms the generation of high levels of
this inactive metabolite after 51657 dosing (Additional
file 1: Figure S1C), suggesting that the extended MT
stabilization observed after 51657 dosing was not likely
due to the formation of an active metabolite. The pro-
longed MT-stabilizing effect of 51657 could also result
from an irreversible MT interaction. However, the crys-
tal structure of a structurally-related TPD molecule
bound to a MT [38], which we have determined is a
TPD+ compound [49], reveals no evidence of a covalent
interaction, suggesting it is unlikely that 51657 binds co-
valently to MTs. Finally, it is possible that a small frac-
tion of 51657 remains non-covalently bound to brain
MTs after the majority of drug clears from the brain,
and that this amount is sufficient to impart increased
AcTub. Regardless of the exact mechanism of this ex-
tended MT-stabilizing effect, our observations suggest
that a long CNS residence time may not be required for
meaningful MT stabilization, as was previously postulated
for the MT-stabilizing agents EpoD and dictyostatin, both
of which had very long brain T1/2 values [25, 50].
It has been reported that TPD molecules that are
structurally related to 51657 are cytotoxic to Pgp-
expressing cancer cell lines [38, 51], indicating that they
are not Pgp substrates. This would differentiate such
TPDs from paclitaxel and related MT-directed taxanes,
as well as many other cancer drugs, which are ineffective
against Pgp-expressing cells. We previously demon-
strated that 51657 is not a competitive Pgp inhibitor
[35], which indicates it does not interact with Pgp. To
further verify an absence of Pgp binding, we examined
the ability of 51657 to inhibit proliferation of Pgp-
expressing ADR-RES cells [52] and compared its activity
to paclitaxel, which is a Pgp substrate. As expected,
51657 (1 μM) promoted a significantly greater cytotox-
icity than did the same concentration of paclitaxel
(Additional file 1: Figure S2). This concentration of pac-
litaxel is at least two orders of magnitude greater than that
required for cytotoxic activity in cell lines not expressing
Pgp [53], and the greater effect of 51657 reveals that it is
an effective cytotoxic agent for Pgp-expressing cells. Given
the excellent brain exposure of 51657, these data would
suggest that TPD+ compounds of this type might hold
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cytomas or glioblastomas, as many anti-cancer agents
have poor brain penetration due to Pgp efflux at the
blood-brain barrier, and there is also evidence of Pgp-
mediated drug resistance in some glioblastomas [54].
However, it is important to note that 51657 was present
continuously in the cell culture medium in these cytotox-
icity studies, and given the short plasma and brain half-life
observed after dosing in mice, it is likely that fre-
quent dosing of this compound would be required to
elicit a meaningful anti-mitotic effect. In fact, as dis-
cussed further below, we observed no signs of cyto-
toxicity or anti-mitotic activity when 51657 was dosed
twice-weekly in tau Tg mice, although this dosing
schedule provided CNS benefit.
Testing of CNDR-51657 in PS19 tau transgenic mice
Given the ability of 51657 to elicit a prolonged increase
of AcTub in the WT mouse brain, we subsequently eval-
uated the compound for efficacy in the PS19 tau trans-
genic mouse model, which expresses human 1N4R tau
harboring the P301S mutation found in inherited
FTLD-tau [40]. We previously utilized this mouse model
in both prevention and intervention studies to demon-
strate the efficacy of EpoD [25, 27] and dictyostatin [32].
In these prior studies, only male PS19 mice were utilized
because they develop tau pathology more rapidly than
female PS19 mice and mixing of age-matched PS19 mice
of both sexes results in unacceptably high variability in
the amount of tau pathology that can mask treatment ef-
fects. Unpublished work from our laboratories revealed
that female PS19 mice will also develop appreciable tau
pathology, albeit with a 5–6-month delay relative to
male PS19 mice. Moreover, young (2–3 month) female
PS19 mice can develop tau pathology to an extent com-
parable to that observed in age-matched male PS19 mice
when synthetic tau fibril “seeds” are introduced into the
brain to initiate the formation of tau pathology [55, 56].
Because female mice can be group-housed to reduce study
costs, we opted to examine 51657 in aged female PS19
mice. Groups of 9-month old female PS19 mice (n = 12/
group) received vehicle, or 3 mg/kg or 10 mg/kg of 51657,
twice-weekly (i.p.) for a total duration of 3 months. In
addition, a group of age-matched non-transgenic female
littermates received twice-weekly administration of ve-
hicle. We anticipated that the 9-month old female PS19
mice would be roughly comparable to 3–4-month old
male PS19 mice with regard to the extent of brain tau
pathology, with the latter showing a low but detectable
tau inclusion burden [25, 56]. Thus, the study was de-
signed to be a secondary prevention assessment of 51657
efficacy, similar to our prior study in which EpoD was
shown to have beneficial effects when dosed in male PS19
mice from 3 to 6 months of age [25]. As in our priorprevention study with EpoD in PS19 mice [25], we exam-
ined MT density and axonal dystrophy in the ON, as well
as brain tau pathology and cognitive performance. In
addition, complete blood cell counts were obtained to de-
termine whether changes in mitotic blood cells were ob-
served upon prolonged treatment with 51657. We were
particularly interested in determining whether compound
treatment affected neutrophils, as neutropenia is a primary
dose-limiting side-effect observed with MT-stabilizing
drugs in cancer patients [57, 58].
The 3-month treatment of PS19 mice with 51657 ap-
peared to be well-tolerated at both doses, as there were
no significant changes in body weight between the ve-
hicle- and 51657-treated PS19 mice. None of the treat-
ment groups showed meaningful body weight loss and
PS19 mice receiving 51657 showed somewhat less body
weight loss than did the vehicle-treated PS19 mice, al-
though this difference did not reach statistical signifi-
cance (Additional file 1: Figure S3). Similarly, there were
no differences in organ weights when normalized to
body weight between the vehicle- and 51657-treated
mice (Additional file 1: Figure S4). Importantly, there
was no evidence of a compound-mediated changes in
blood cells, as total white blood cells (Fig. 2a), red blood
cells (Fig. 2b) and neutrophils (Fig. 2c) were unchanged
in 51657-treated mice relative to either PS19 or WT
mice receiving vehicle only.
To assess whether 51657 improved MT density in the
treated PS19 mice, as previously observed with EpoD
[25, 27] and dictyostatin [32], ON segments were re-
moved from the study mice after perfusion and sacrifice,
and were fixed to allow for EM analysis of MTs in
cross-sectional images via blinded quantification. As pre-
viously observed in 6-month old male PS19 mice [25],
12-month old vehicle-treated female PS19 mice showed
reduced ON MT density relative to age-matched
vehicle-treated non-transgenic littermates (Fig. 3a and
c). Notably, the PS19 mice receiving either 3 mg/kg or
10 mg/kg of 51657 had a significant increase in MT
density that reached the value observed in the WT mice
(Fig. 3a). Thus, the twice-weekly dosing scheme with
51657 had the desired effect of abrogating the MT def-
icit observed in the PS19 mice, with the magnitude of
MT enhancement being similar to that previously ob-
served with EpoD [25]. In prior studies with PS19 mice,
a reduction of ON MTs coincided with a significant in-
crease in ON axonal dystrophy, with an abundance of
swollen and demyelinated axons observed upon EM ana-
lysis [25, 27, 32]. An increase in dystrophic axons was
also observed in the 12-month old female PS19 mice
from the current study, and both doses of 51657 led to a
dramatic lowering of ON axonal dystrophy to the level
observed in the vehicle-treated WT mice (Fig. 3b and d).
These results provide further evidence of 51657 having
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Fig. 2 PS19 mouse blood cells were unaffected by 12 weeks of 51657
dosing. Total blood cell counts were determined for WT mice receiving
vehicle (n = 10) or PS19 mice receiving vehicle (n = 6), 3 mg/kg of
51657 (n = 7) or 10 mg/kg of 51657 (n = 8). No differences in (a) total
white cell counts, (b) red cell counts or (c) neutrophil counts were
observed between the vehicle- and 51657-treated mice as determined
by one-way ANOVA. Error bars represent SEM
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axonal integrity and function.
One hemisphere from each brain of the study mice was
flash frozen for biochemical measurement of insoluble tau
pathology, and the other hemisphere was fixed for immu-
nohistochemical (IHC) evaluation. In our prior prevention
study of EpoD in young male PS19 mice, we observed a
modest amount of AT8 (pS202/pT205)-positive tau path-
ology in 6-month old male PS19 mice upon IHC assess-
ment, with a non-significant trend toward reduced
pathology in the EpoD-treated mice [25]. A significant re-
duction of tau pathology was seen in an intervention study
in older PS19 mice with greater tau pathology [27]. An
examination of AT8-positive tau in the 12-month old fe-
male PS19 mice via IHC analysis revealed somewhat less
tau pathology than previously observed in 6-month old
male PS19 mice, with the amount of AT8 staining being
low-to-moderate in vehicle-treated female PS19 mice
(Fig. 4a) with significant mouse-to-mouse variability, as
previously observed with male PS19 mice [25, 27]. None-
theless, we attempted to quantify the AT8-positive stain-
ing, with analysis of the hippocampus and entorhinal
cortex where the majority of tau pathology was observed
(Fig. 4a). A blinded assessment of three Bregma-matched
sections from each study mouse revealed a non-significant
trend toward a reduction of combined cortical and hippo-
campal AT8-positive staining in the 51657-treated mice
(Fig. 4b) that resembled the results previously observed in
the prevention study with EpoD in PS19 mice. As previ-
ously observed in 6-month old male PS19 mice [25],
NeuN staining of neurons revealed no evidence of hippo-
campal CA3 neuron loss in the female PS19 mice of this
study (Additional file 1: Figure S5), a brain region where
significant neuron loss is observed in PS19 mice with
greater pathology [27]. This is consistent with the rela-
tively modest level of tau pathology observed in these
mice.
Given the generally low amount of tau pathology ob-
served by AT8-staining in the 12-month old female
PS19 mice, a degree of regional variability in the location
of AT8-positive tau and the semi-quantitative nature of
IHC measurements, we also conducted biochemical as-
sessments of tau pathology since such analyses are gen-
erally more quantitative than IHC. The entire cortex and
hippocampus from frozen brain hemispheres from each
PS19 mouse were subjected to sequential extraction,
CA
D
Fig. 3 PS19 mice treated with 51657 had significantly increased ON MT density and reduced axonal dystrophy. ON sections from vehicle-treated
WT mice (n = 10) and PS19 mice treated with vehicle (n = 9) or 3 mg/kg (n = 8) or 10 mg/kg (n = 10) of 51657 were imaged by EM, and the
number of MTs and dystrophic axons within treatment-masked images were counted as previously described [25]. a Quantification of MT density
in ON sections demonstrates that vehicle-treated PS19 mice have a MT deficit relative to vehicle-treated WT mice, and treatment of PS19 mice
with 3 mg/kg or 10 mg/kg of 51657 increases MT density to a level comparable to that of WT mice. b Quantification of ON EM images reveals a
significant reduction in axonal dystrophy in PS19 mice receiving either 3 mg/kg or 10 mg/kg of 51657 compared to vehicle-treated PS19 mice.
After quantification, a Grubb’s test determined there was an extreme outlier within the 10 mg/kg 51657 group that was not used for
quantification. Analyses consisted of a one-way ANOVA with Tukey’s post-hoc analysis of between group differences. Error bars represent
SEM. c Representative ON images from a vehicle-treated WT and PS19 mouse, with example MTs indicated by arrows. As depicted in the
PS19 vehicle image, hexagonal fields of 0.035 μm2 were overlaid on the ON images, with MTs counted within the hexagon and on three
of the six borders to avoid repeat counting of MTs of MTs on adjacent hexagons (see also [27]). Scale bar represents 0.5 μM. d Representative ON
images from a vehicle-treated WT and PS19 mouse, as well as a PS19 mouse that received a twice-weekly dose of 10 mg/kg of 51657. Vehicle-treated
PS19 mice have greater axonal dystrophy, as evidenced by fewer intact axons and more axons that are demyelinated or debris-filled, than vehicle-
treated WT mice. ONs of PS19 mice treated with 51657 more closely resembled those of vehicle-treated WT mice. Scale bar = 2 μm
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centrifugation, with subsequent extraction of the pellet in
RIPA buffer with centrifugation. The remaining high salt-
and RIPA-insoluble pellet fraction was solubilized in SDS
and analyzed by immunoblotting to determine the
amount of total tau, AT8-positive phosphorylated tau, and
K280-acetylated tau [44] in the buffer-insoluble fraction.Both AT8 and acetyl-K280 tau have been shown to be
enriched in pathological tau, with the latter appearing in
more mature tau inclusions [59, 60]. The samples were
blinded prior to gel loading and quantification, and the re-
sults revealed that the 3 mg/kg dose of 51657 led to a sig-
nificant reduction of insoluble total tau (Fig. 5a),
AT8-positive tau (Fig. 5b) and acetyl-K280-positive tau
AB
Fig. 4 IHC staining and quantification of tau pathology. Three bregma-matched brain sections from each PS19 mice receiving vehicle (n = 12), or
3 mg/kg (n = 11) or 10 mg/kg (n = 12) of 51657, were stained with AT8 antibody to visualize tau pathology. a Representative images from a
vehicle-treated PS19 mouse with an average amount of tau pathology (Bregma − 2.5). Regions of stained sections encompassing the
hippocampus and entorhinal cortex were imaged and a fixed threshold was applied to distinguish AT8-positive staining from background
(images on right; yellow, low AT8 signal; orange, moderate AT8 signal; red, high AT8 signal), followed by quantification of AT8-positive
tau pathology. b A plot of the combined AT8-positive pathology from the entorhinal cortex and hippocampus from PS19 mice in each
treatment group reveals a trend toward reduced tau pathology in the 51657-treated mice
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dose of 51657 caused a significant reduction of insoluble
acetyl-K280 tau (Fig. 5c and Additional file 1: Figure S6),
although the observed decrease in insoluble AT8-positive
tau and total insoluble tau did not reach statistical signifi-
cance (Fig. 5a and b). A comparison of the amount of in-
soluble AcTau in 9-month old female PS19 mice (i.e., start
of treatment) to that within 12-month female PS19 mice
suggests that there is roughly a doubling of the amount of
mature pathological tau over the 3-month treatment
period (Additional file 1: Figure S7), and thus an ~ 50% re-
duction of tau pathology would be expected if 51657 treat-
ment led to a cessation of further pathology development.This is approximately the effect size observed in the
51657-treated PS19 mice (Fig. 5). As the amount of insol-
uble AT8-positive and total insoluble tau did not differ
significantly between the 3 mg/kg and 10 mg/kg 51657
treatment groups, we cannot conclude that the higher
dose was less effective than the lower dose, particularly
since both doses significantly improved MT density and
reduced axonal dystrophy. The reductions in insoluble tau
species in the PS19 mice receiving 51657 were not due to
an overall reduction in tau protein expression, as soluble
tau levels were not significantly different in the vehicle-
and 51657-treated PS19 mice (Fig. 5d). An assessment of
GFAP-positive astrocytes and Iba1-positive microglia did
A B
C D
µ
Fig. 5 PS19 mice treated with 51657 show a reduction of insoluble pathological forms of tau. Brains of PS19 mice treated with vehicle (n = 12),
or 3 mg/kg (n = 11) or 10 mg/kg (n = 12) of 51657 were sequentially extracted to remove high salt- and RIPA-soluble proteins. The remaining
insoluble fraction was solubilized in 2% SDS and analyzed by immunoblotting, utilizing antibodies that recognize (a) total tau (17025 antibody),
(b) phospho-tau (AT8 antibody) and (c) tau acetylated at residue K280 (AcTau; tau K280 antibody). The lower dose of 51657 caused a significant
reduction of all three forms of insoluble tau, and the higher dose of 51657 dose resulted in a reduction of all insoluble tau species, with a
significant reduction of AcTau. After quantification, a Grubb’s test determined there were extreme outliers within some treatment groups,
resulting in the removal of a sample (B2) from the 10 mg/kg 51657 group from the AcTub antibody immunoblot (see Additional file 1: Figure S6),
and a sample from each treatment group in the 17025 antibody immunoblot. d Soluble tau levels as measured by ELISA within the high salt
fractions were unaffected by 51657-treatment. All comparisons consisted on one-way ANOVA with Tukey’s post-hoc analysis of between group
differences. Error bars represent SEM
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ology in any PS19 mouse treatment group (Additional file
1: Figure S8), suggesting that the reduction of tau
pathology in the 51657-treated mice was not due to
compound-induced effects on glia. In summary, these data
reveal that 51657 treatment led to a reduction of insoluble
tau pathology in the PS19 mice, as previously demon-
strated for EpoD in an interventional study [27] and for
which there was a trend toward reduction upon EpoD
treatment in a prior prevention study [25]. These changes
in tau pathology are believed to result directly from
compound-mediated effects on MTs.
We have previously observed mild cognitive deficits in
male PS19 mice as young as 6 months of age [25]. Thus,
the female PS19 mice and littermate controls within this
study underwent testing in the Barnes maze shortly after
receiving their last vehicle or compound administration.
As summarized in Fig. 6, there was a trend towards im-
paired performance by the vehicle-treated female PS19
mice relative to vehicle-treated non-transgeniclittermates during the first two days of testing, as mea-
sured by their success in identifying an escape compart-
ment, with the 51657-treated PS19 mice performing
somewhat better than the vehicle PS19 group on these
days. However, group variability was relatively large and
these differences did not reach statistical significance.
All treatment groups showed nearly complete learning
by days 3 and 4 of testing, which in light of the modest
amount of tau pathology and absence of neuron loss in
the 12-month old female PS19 is not surprising. Thus,
the totality of study data reveal that treatment of female
PS19 mice with 51657 from 9- to 12-months of age in a
secondary prevention model led to significantly im-
proved MT density and reduced axonal dystrophy, with
a resulting reduction of tau pathology and a trend to-
ward improved cognitive performance.
Discussion
The concept of utilizing MT-stabilizing agents to treat
tauopathies has been discussed for some time [31], and
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Fig. 6 Barnes maze testing of WT and PS19 mice treated with vehicle or 51657. The vehicle-treated PS19 mice had a modest deficit relative to
vehicle-treated WT mice in successfully identify the escape compartment in the maze during the first two days of testing, and the PS19 mice
receiving 51657 showed a non-significant trend toward improvement on day 1 and 2 compared to the vehicle group. Because of the modest
amount of tau pathology and absence of overt neuron loss in the 12-month female PS19 mice, the behavioral deficits were mild and all
treatment groups showed nearly 100% performance by the third and fourth days of testing
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years have demonstrated the potential of this therapeutic
strategy in tauopathy mouse models [24–27, 32, 61, 62],
as well as in other tau model systems [63, 64]. Among
traditional small molecule MT-stabilizing compounds,
both EpoD and the abeotaxane, TPI-287, have pro-
gressed to Phase 1b clinical testing, where each was ex-
amined in short 2–3 month studies in AD and/or
tauopathy patients. Both of these drug candidates ap-
peared to be well tolerated at the tested doses [65].
Interestingly, TPI-287 treatment was reported to result
in a significant improvement in AD patient MMSE
scores relative to the placebo group after 12 weeks of
drug dosing (www.corticebiosciences.com; 11/03/17
press release). However, given the very short duration of
these Phase 1b trials and the small number of patients
evaluated, we believe caution should be exercised in
drawing either positive or negative inferences about the
potential of MT-stabilizing agents in neurodegenerative
disease from these studies, particularly since disease-
modifying trials for AD are typically at least 18–
24 months in length.
It is unclear whether either BMS-241027/EpoD or
TPI-287 will advance into larger clinical studies of lon-
ger duration. Given this and the fact that both of these
natural product-derived molecules bind the taxane-site
on MTs, we have further investigated the TPD series of
small molecule MT-stabilizing molecules which bind to
a distinct region on MTs [38], with the goal of identify-
ing alternative and potentially improved candidates for
development as disease-modifying drugs for AD and
other neurodegenerative diseases. Such molecules have
potential advantages over the existing classes of
MT-stabilizing natural products, especially in terms of
drug-like physicochemical properties and syntheticaccessibility. As previously detailed [35], we discovered
that the TPDs could be broadly categorized into two dis-
tinct groups; those that elicit an undesirable bell-shaped
concentration-response profile in in vitro models with
an induction of proteasome-mediated tubulin degrad-
ation, and a smaller set referred to as TPD+ compounds
that are generally characterized by the absence of a para
alkoxy side-chain on the phenyl group and which exhibit
the desired properties of increasing MT stability and MT
mass in cellular models [35].
The in vivo characterization of various TPD+ exam-
ples revealed that nearly all have excellent brain expos-
ure [35], and we selected 51657 as a prototype for more
complete in vivo testing. Although 51657 was found to
have a relatively short plasma and brain half-life, the
compound caused a significant increase in brain AcTub
that could be observed up to 3 days after cessation of
dosing. This suggests that MT stabilization persists after
most, if not all, of the compound is cleared from the
brain. We are unsure of the mechanism of this lasting
effect, but perhaps tubulin acetylation or other tubulin
post-translational modifications that occur after initial
compound-mediated stabilization contribute to pro-
longed MT activity [39]. Importantly, these data indicate
that long brain half-life may not be a necessity for a
beneficial MT-stabilizing effect, as was previously sug-
gested based on the long brain retentions of EpoD and
dictyostatin [41, 50]. Thus, MT-stabilizing agents with
shorter brain half-lives, such as 51657, might provide ad-
vantages over the previously examined natural products
in that they would still allow for relatively infrequent
dosing but with a reduced risk of compound accumula-
tion in the brain and other tissues after repeated dosing.
The ability of 51657 to improve CNS MT density and
reduce axonal dystrophy in PS19 mice with twice-weekly
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stabilizing compound with a relatively short half-life can
be efficacious. The extent of 51657-mediated improve-
ment in MT density in the PS19 tau transgenic mice was
comparable to that previously observed with EpoD [25,
27], as was the compound-induced reduction in axonal
dystrophy. Moreover, 51657 treatment led to a reduction
in insoluble pathologic tau in PS19 mice, as has been ob-
served for both EpoD [24, 25] and dictyostatin [32]. The
observations of MT-stabilizing agents reducing tau path-
ology in tau Tg mice is interesting and arguably somewhat
unexpected since compounds that improve MT structure/
function would not necessarily be expected to affect the
accumulation of misfolded tau. However, it has previously
been demonstrated that there is a relationship between
impaired axonal transport and tau pathology, as genetic-
ally crossing mice with defective kinesin-1 function with
tau Tg mice resulted in an exacerbation of tau pathology
that may have resulted, at least in part, from JNK pathway
activation [66, 67]. Thus, it might be expected that, con-
versely, normalization of MT function and axonal trans-
port in PS19 mice with a MT-stabilizing agent would lead
to a reduction of tau pathology.
Our data reveal that a brain-penetrant MT-stabilizing
TPD+ molecule that is readily synthesized can provide
meaningful benefit in an established mouse model of
tauopathy. Moreover, the lack of effect on dividing blood
cells after twice-weekly 51657 administration indicates
that axonal MTs can be modulated to provide CNS
benefit while avoiding the untoward side-effects ob-
served when high doses of MT-stabilizing drugs are used
for the treatment of cancer. Interestingly, the TPD+
molecules described here bind to MTs at a site that is
distinct from the binding site of taxanes, epothilones
and dictyostatin, with TPD+ molecules interacting at the
vinca alkaloid site on MTs [38]. Notably, the binding of
vinblastine and vincristine to this site results in MT
depolymerization [68], and thus TPD+ compounds are
unique in their ability to stabilize MTs through inter-
action at this site. Moreover, TPD+ molecules appear to
promote stability through longitudinal tubulin contacts
in MTs, and importantly, do not enhance lateral MT
contacts as observed with compounds that bind the tax-
ane site [38]. Thus, 51657 and related TPD+ molecules
provide a promising class of brain-penetrant and orally
bioavailable MT-stabilizing agents. In addition, 51657
and other TPD molecules generally do not interact with
Pgp, unlike EpoD [35] and many taxanes [53, 69]. The
absence of Pgp binding provides a potential safety bene-
fit, as this transporter prevents xenobiotics from enter-
ing the brain and thus inhibitors of Pgp could increase
brain exposure to unwanted molecules. Moreover, the
brain and a number of tumors exclude MT-stabilizing
drugs through Pgp efflux, and thus higher or morefrequent doses of 51657 or other non-Pgp binding TPD
molecules might have utility for the treatment of tumors
that are resistant to existing MT-directed drugs, particu-
larly brain tumors.Conclusions
We demonstrate for the first time that a vinca
site-binding TPD+ compound (51657) with favorable
drug-like properties is capable of increasing CNS MT
stabilization in an established mouse model of tauopathy
at a relatively low dose administered twice-weekly, with
a resulting reduction of axonal dystrophy and tau path-
ology in the brain. These beneficial effects are compar-
able to what we and others have found in mouse
tauopathy models with MT-stabilizing natural products
like paclitaxel [26], EpoD [24, 25, 27] and dictyostatin
[32] that bind the taxane-site on MTs. These results thus
reveal that brain-penetrant TPD+ molecules hold con-
siderable promise for the treatment of AD and related
tauopathies, as well as possibly additional neurodegener-
ative disorders [22].Additional file
Additional file 1: Figure S1. Metabolism of 51657. Figure S2. ADR-Res
cells expressing Pgp are more sensitive to 51657 than to paclitaxel.
Figure S3. Normalized WT and PS19 mouse body weights over time
while receiving twice-weekly dosing of vehicle or 51657 (3 mg/kg or
10 mg/kg). Figure S4. PS19 mouse organ weights were unaffected by
12 weeks of 51657 dosing. Figure S5. Quantification of NeuN-positive
neurons within the CA3 region of the hippocampus of 12-month old female
WT mice or vehicle- or 51657-treated female PS19 mice. Figure S6.
Composite images of the three blots utilized in quantification of insoluble
AcTau as shown in manuscript Fig. 5c. Figure S7. A comparison of insoluble
AcTau levels in 9-month old and 12-month old female PS19 mice.
Figure S8. Representative 40× images of hippocampal dentate region
from brain sections of vehicle- or 51657-treated PS19 mice stained to
visualize astrocytes and microglia. Table S1. Crystal data and structure
refinement for CNDR-51657. Table S2. Atomic coordinates (× 104) and
equivalent isotropic displacement parameters (Å2x 103) for CNDR-51657.
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